We are live on
!
Find out more
EC
Elmind Capital Portfolio holdings
AUM
$352M
This Fund
S&P 500
This Quarter
Est. Return
+12.77%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$352M
AUM Growth
+$13.4M
(+3.9%)
Cap. Flow
-$7.13M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
68.76%
Holding
36
New
2
Increased
7
Reduced
6
Closed
2
Top Buys
| 1 |
CytomX Therapeutics
CTMX
|
+$19.5M |
| 2 |
DBVT
DBV Technologies
DBVT
|
+$5.54M |
| 3 |
KALV
KalVista Pharmaceuticals
KALV
|
+$3.55M |
| 4 |
ALMS
Alumis Inc
ALMS
|
+$3.25M |
| 5 |
Cullinan Oncology
CGEM
|
+$2.83M |
Top Sells
| 1 |
CG Oncology
CGON
|
+$11.4M |
| 2 |
DVAX
Dynavax Technologies
DVAX
|
+$10.5M |
| 3 |
Viridian Therapeutics
VRDN
|
+$9.61M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$8.93M |
| 5 |
Wave Life Sciences
WVE
|
+$3.52M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Design Therapeutics
DSGN
$866M
| $2.21M | 0.63% |
207,900
| – | – |
|
|
APLS
27
DELISTED
Apellis Pharmaceuticals
APLS
| $2.01M | 0.57% |
50,000
| – | – |
|
28
Alector
ALEC
$168M
| $1.94M | 0.55% |
900,000
| – | – |
|
29
Immunocore
IMCR
$1.65B
| $1.76M | 0.5% |
58,248
| – | – |
|
30
Amylyx Pharmaceuticals
AMLX
$1.94B
| $1.56M | 0.44% |
112,000
| – | – |
|
31
enGene Therapeutics
ENGN
$125M
| $1.43M | 0.41% |
210,000
| – | – |
|
|
32
Wave Life Sciences
WVE
$1.14B
| $1.29M | 0.37% |
177,846
-270,000
| -60% | -$3.52M |
|
33
Supernus Pharmaceuticals
SUPN
$2.75B
| $1.03M | 0.29% |
20,000
| – | – |
|
34
Edgewise Therapeutics
EWTX
$4.44B
| $315K | 0.09% |
10,000
-20,000
| -67% | -$577K |
|
|
DVAX
35
DELISTED
Dynavax Technologies
DVAX
| – | – |
-679,900
| Closed | -$10.5M |
|
36
Liquidia Corp
LQDA
$6.33B
| – | – |
-90,000
| Closed | -$3.1M |
|
Similar funds
PIC
MCMU
SC
FWM
BMWM
ACA
BFS
BL